Last updated: August 4, 2026
Onyx Therapeutics, Inc. v. Aurobindo Pharma USA, Inc., No. 1:17-cv-01699-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Aurobindo’s proposed generic version of Kyprolis (carfilzomib) for injection. Onyx alleged that Aurobindo’s abbreviated new drug application, or ANDA, infringed U.S. Patent No. 8,207,125. The case ended without a reported merits decision. The public docket reflects a negotiated resolution and dismissal, while the settlement’s commercial terms were not made public.[1]
The case was important because the asserted patent covered carfilzomib treatment regimens used in multiple myeloma. The dispute therefore concerned a method-of-use patent rather than only the chemical composition of carfilzomib.
What was Onyx Therapeutics v. Aurobindo about?
Onyx sued after receiving notice that Aurobindo had submitted an ANDA seeking FDA approval to market generic carfilzomib for injection. Kyprolis was developed by Onyx and later became part of Amgen’s oncology portfolio following Amgen’s acquisition of Onyx.[2]
The litigation involved:
| Item |
Detail |
| Case |
Onyx Therapeutics, Inc. v. Aurobindo Pharma USA, Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:17-cv-01699-RGA |
| Filing period |
2017 |
| Plaintiff |
Onyx Therapeutics, Inc. |
| Defendant |
Aurobindo Pharma USA, Inc. |
| Product |
Kyprolis, carfilzomib for injection |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Main patent identified in the action |
U.S. Patent No. 8,207,125 |
| Patent subject |
Carfilzomib compositions and methods of use |
| Outcome |
Resolved and dismissed without a reported trial or final infringement judgment |
The case was one of several generic challenges involving carfilzomib and other proteasome-inhibitor products. Its commercial significance depended on whether Aurobindo could obtain final FDA approval and launch before the expiration or licensed entry date associated with the asserted patent.
What patents protected Kyprolis in the Aurobindo case?
The principal patent asserted against Aurobindo was U.S. Patent No. 8,207,125. The patent is associated with carfilzomib compositions and therapeutic methods, including dosing approaches for treating multiple myeloma.[1]
U.S. Patent No. 8,207,125
| Field |
Information |
| Patent number |
8,207,125 |
| General subject |
Carfilzomib compositions and methods of use |
| Patent type |
Therapeutic method and formulation-related claims |
| Applicant or assignee history |
Onyx-related ownership |
| Relevance to Kyprolis |
Covers treatment approaches using carfilzomib |
| Expected statutory term |
Based on a 2007 priority framework, subject to patent-term adjustment and statutory calculations |
| Litigation role |
Asserted against Aurobindo’s ANDA product |
Kyprolis contains carfilzomib, a selective proteasome inhibitor. The drug is supplied as a sterile lyophilized powder for intravenous administration and is reconstituted before infusion. The asserted claims were relevant because Aurobindo’s proposed labeling could direct physicians to use the generic product in a manner falling within the patent claims.
A method-of-use patent can create infringement exposure even when the generic manufacturer does not copy the branded product’s formulation in every respect. Under 35 U.S.C. § 271(e)(2), submission of an ANDA with a proposed label can create a technical act of infringement for purposes of resolving patent rights before FDA approval.[3]
When did Kyprolis lose exclusivity?
Kyprolis did not have a single exclusivity date. Its commercial protection consisted of FDA regulatory exclusivity, listed patents, patent-term adjustments, pediatric exclusivity, and any settlement-based launch restrictions.
FDA regulatory exclusivity
Kyprolis received FDA approval in July 2012 for patients with multiple myeloma who had received at least two prior therapies, including bortezomib and an immunomodulatory agent, and whose disease had progressed on or after the last therapy.[4]
The FDA later expanded Kyprolis indications, including combination use with lenalidomide and dexamethasone and with dexamethasone alone. These approvals created additional method-of-use protection and expanded the commercial value of the product.[4]
For a conventional small-molecule drug, five-year new chemical entity exclusivity generally prevents submission of an ANDA for four years and delays approval for five years. That period would have expired before the 2017 Aurobindo litigation. The practical barrier in this case was therefore patent protection, not initial NCE exclusivity.
Patent expiration
The expiration date for any Kyprolis patent depends on the specific patent, terminal disclaimers, patent-term adjustment, and pediatric extension. U.S. Patent No. 8,207,125 was filed against a priority date in 2007 and had a nominal 20-year patent term measured from the applicable nonprovisional filing date, subject to statutory adjustments.[1]
The public litigation record does not establish that the court issued a final ruling fixing an effective expiration date for every Kyprolis patent. The case ended through resolution rather than judgment. Commercial launch timing therefore depended on the settlement and the remaining patent estate, not only on the nominal expiration date of the asserted patent.
Was this a Paragraph IV challenge?
Yes. Aurobindo’s ANDA activity triggered a Paragraph IV patent dispute. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. Onyx treated Aurobindo’s ANDA submission and notice as an act of infringement under the Hatch-Waxman framework and filed suit within the statutory 45-day period.[1,3]
A Paragraph IV filing creates several business consequences:
- The branded company can obtain a 30-month stay of FDA approval if it files suit within 45 days after receiving notice.
- The generic applicant gains a potential 180-day first-filer exclusivity period if it is the first eligible Paragraph IV applicant and satisfies the statutory requirements.
- The generic applicant can challenge patent claims before a commercial launch, reducing the risk of an immediate post-approval injunction.
- The branded company must defend both patent validity and infringement while preserving the product’s FDA and commercial position.
The public case record does not show a reported Delaware claim-construction ruling, summary-judgment decision, or trial verdict in the Aurobindo action.
What was the litigation timeline?
| Date or period |
Event |
| July 2012 |
FDA approved Kyprolis for specified multiple myeloma patients.[4] |
| 2017 |
Aurobindo submitted an ANDA for generic carfilzomib for injection and provided Paragraph IV notice. |
| 2017 |
Onyx filed Civil Action No. 1:17-cv-01699 in Delaware.[1] |
| 2017-2018 |
The parties litigated the ANDA patent dispute. |
| Later proceeding |
The parties resolved the action through a negotiated disposition. |
| Final procedural status |
The action was dismissed pursuant to the parties’ resolution, without a reported merits judgment.[1] |
The docket does not provide a public judicial opinion determining whether the asserted patent was valid, enforceable, or infringed. It therefore should not be cited as precedent on the scope or strength of the carfilzomib claims.
What was the outcome of the Aurobindo Kyprolis lawsuit?
The lawsuit ended by settlement or another negotiated resolution reflected in the dismissal record. The public materials do not disclose the principal economic terms, including:
- The authorized launch date for Aurobindo;
- Whether the agreement included a royalty;
- Whether Aurobindo received a license;
- Whether the parties agreed to an acceleration clause;
- Whether the agreement included supply, manufacturing, or transition provisions; or
- Whether the agreement affected other carfilzomib applicants.
There was no reported trial verdict invalidating U.S. Patent No. 8,207,125. There was also no reported injunction after trial. The procedural outcome preserved Onyx’s ability to avoid an adverse patent ruling while giving Aurobindo a negotiated path toward eventual market entry.
What was the Orange Book status of Kyprolis?
Kyprolis is an FDA-approved prescription oncology product, and its patent rights are evaluated through the FDA’s Orange Book listing system. The Orange Book identifies patents submitted by the NDA holder and provides patent-use information for approved drug products.[5]
The relevant Orange Book analysis has several limits:
- Orange Book listing does not establish that a patent is valid or infringed.
- A patent may be listed for a method of use even when the drug’s active ingredient is known.
- Generic applicants can submit Paragraph IV certifications against listed patents.
- FDA approval timing can be delayed by litigation, settlement restrictions, pediatric exclusivity, or other statutory mechanisms.
- The existence of an Orange Book listing does not reveal confidential settlement terms.
For Kyprolis, the commercially relevant patent question was not only whether carfilzomib itself remained patented. It was whether Aurobindo’s proposed product and label would practice patented treatment methods or fall within protected product claims.
How strong was Onyx’s patent estate?
Onyx’s estate had meaningful commercial value because it combined:
- The carfilzomib active ingredient;
- Carfilzomib compositions;
- Treatment methods for multiple myeloma;
- Dose-escalation and administration regimens;
- FDA-approved indication coverage; and
- Potential Orange Book-listed patents.
Its strength was more dependent on claim scope and label strategy than on the number of patents alone. A broad composition patent can block a generic product directly. A method-of-use patent is more vulnerable to a label carve-out if the generic applicant can omit the patented indication or dosing instruction while retaining approval for unprotected uses.
Technical and manufacturing barriers
Carfilzomib is not a simple oral solid dosage product. Kyprolis is an injectable oncology product requiring:
- Sterile manufacturing;
- Control of peptide-related impurities;
- Lyophilization;
- Reconstitution stability;
- Container-closure integrity;
- Validated potency and sterility testing; and
- Compliance with injectable-product current good manufacturing practices.
Those technical requirements create regulatory and manufacturing barriers independent of patent litigation. They do not, however, replace patent protection. A capable injectable manufacturer can overcome those barriers while still facing composition, formulation, process, and method-of-use patents.
Which companies challenged Kyprolis exclusivity?
Aurobindo was one of the companies pursuing a generic carfilzomib pathway. Other generic or specialty pharmaceutical companies could also challenge Kyprolis patents through ANDA filings, but each applicant’s risk profile depends on its certification, proposed label, manufacturing process, and settlement position.
The competitive landscape included:
| Competitor type |
Main risk to Kyprolis |
| ANDA applicants |
Paragraph IV litigation and potential launch after settlement or patent expiry |
| Injectable generic manufacturers |
Pricing pressure after FDA approval |
| Other proteasome inhibitors |
Therapeutic substitution and formulary competition |
| Multiple myeloma therapies |
Competition from bortezomib, ixazomib, daratumumab, lenalidomide, and combination regimens |
| Biosimilar developers |
Limited direct relevance because carfilzomib is a small molecule, not a biologic |
Was there biosimilar risk for Kyprolis?
No conventional biosimilar pathway applied. Carfilzomib is a small-molecule active ingredient regulated through the ANDA pathway, not a biologic regulated under the Public Health Service Act biosimilar framework.
The relevant competitive threat was generic entry. A generic carfilzomib product could be approved through an ANDA if it demonstrated pharmaceutical equivalence, bioequivalence where applicable, and compliance with FDA manufacturing and labeling requirements.
What generic launch risks existed?
Aurobindo’s potential launch risk depended on five variables:
- Patent validity. A successful invalidity challenge could have enabled earlier entry.
- Infringement. A noninfringing label or manufacturing process could have reduced exposure.
- Settlement terms. A negotiated license could establish a fixed launch date before patent expiry.
- FDA approval. Patent resolution alone would not guarantee final approval.
- Product quality. Injectable manufacturing deficiencies could delay approval after patent resolution.
For Onyx and Amgen, the principal risk was an earlier-than-expected generic launch that would reduce Kyprolis net sales and weaken pricing. For Aurobindo, the principal risk was spending heavily on an ANDA and litigation without obtaining a commercially useful approval date.
How did the case affect Kyprolis revenue exposure?
Kyprolis is a high-value oncology product, and generic entry could affect revenue through:
- Lower average selling price;
- Greater payer substitution;
- Reduced hospital and clinic purchasing leverage;
- Loss of share in multiple myeloma combinations;
- Increased contracting pressure; and
- Declining revenue after multiple competitors enter.
A single approved generic does not always produce immediate full erosion for an injectable oncology drug. Distribution capacity, hospital contracting, physician familiarity, and supply reliability can delay or moderate substitution. Once several manufacturers enter, erosion generally accelerates.
Because the Aurobindo settlement terms were not public, the case record does not establish the precise revenue impact or launch date attributable to Aurobindo.
Did the case create legal precedent?
No reported merits decision from the action established precedent on Kyprolis patent validity, claim construction, or infringement. The case is best understood as a private ANDA dispute resolved through negotiated dismissal.
Its legal importance is practical rather than precedential:
- It confirms that carfilzomib method-of-use rights were actively enforced against generic applicants.
- It illustrates the commercial role of Paragraph IV litigation in managing injectable oncology products.
- It shows that settlement can preserve patent value without exposing the branded company to a trial judgment.
- It does not establish that the asserted patent would have survived an invalidity challenge or covered Aurobindo’s final commercial label.
Key Takeaways
- Onyx Therapeutics sued Aurobindo in Delaware over an ANDA for generic carfilzomib for injection.
- Kyprolis was the branded product, and U.S. Patent No. 8,207,125 was the principal patent identified in the action.
- The dispute was a Paragraph IV Hatch-Waxman case involving carfilzomib treatment methods and related compositions.
- The case ended through negotiated resolution and dismissal, not a reported trial or merits judgment.
- Public records do not disclose the settlement’s launch date, royalty structure, or license terms.
- Carfilzomib is a small molecule, so generic rather than biosimilar competition is the relevant entry threat.
- Kyprolis protection depended on the combined effect of Orange Book patents, FDA exclusivity, method-of-use claims, formulation rights, and sterile manufacturing requirements.
FAQs
What drug was at issue in Onyx Therapeutics v. Aurobindo?
The case concerned Kyprolis, an injectable formulation of the proteasome inhibitor carfilzomib used to treat multiple myeloma.
What was U.S. Patent No. 8,207,125 directed to?
The patent covered carfilzomib-related compositions and therapeutic methods, including treatment approaches relevant to Kyprolis.
Did Aurobindo launch generic Kyprolis immediately after the lawsuit?
The public litigation record does not establish an immediate launch. The action was resolved through a negotiated disposition, and the settlement’s commercial launch terms were not publicly disclosed.
Is Kyprolis subject to biosimilar competition?
No. Carfilzomib is a small-molecule drug. Competing products would generally proceed through the FDA’s ANDA generic-drug pathway rather than the biosimilar pathway.
Did a court invalidate the Kyprolis patent in this case?
No reported decision in the action invalidated U.S. Patent No. 8,207,125 or determined that Aurobindo’s product infringed. The case ended without a reported merits judgment.
References
- U.S. District Court for the District of Delaware. (2017). Onyx Therapeutics, Inc. v. Aurobindo Pharma USA, Inc., No. 1:17-cv-01699-RGA. PACER docket records.
- Amgen Inc. (2013). Amgen completes acquisition of Onyx Pharmaceuticals.
- Hatch-Waxman Amendments, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
- U.S. Food and Drug Administration. (2012). Kyprolis (carfilzomib) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
